Copper Exploration Heating Up
Canada is already known as a miner's paradise. But British Columbia (BC) is quietly becoming the new copper hotspot. That's because copper is critical to the world's shift to renewable energy. Biden earmarked $226 billion in new infrastructure projects all requiring copper.
Discover Opportunities in the New Copper Hotspot
Nello Mainolfi, insider at Kymera Therapeutics

Nello Mainolfi Insider Information

Nello started his drug discovery career at the Novartis Institutes for Biomedical Research, leading teams to identify multiple novel potential medicines that have entered clinical development across a series of disease areas. Notably he led the team that discovered and developed the first complement factor B inhibitor now in late clinical development across a range of indications. Before founding Kymera, Mainolfi was an Entrepreneur in Residence at Atlas Venture and had previously led discovery research at cancer metabolism startup Raze Therapeutics. Nello has authored >60 papers and patents and has written reviews in the areas of medicinal chemistry, drug discovery and protein degradation. Nello was trained at Imperial College, University of London and The Scripps Research Institute in California.

What is Nello Mainolfi's net worth?

The estimated net worth of Nello Mainolfi is at least $7.11 million as of August 4th, 2021. Dr. Mainolfi owns 457,868 shares of Kymera Therapeutics stock worth more than $7,106,111 as of May 18th. This net worth estimate does not reflect any other assets that Dr. Mainolfi may own. Additionally, Dr. Mainolfi receives a salary of $832,620.00 as CEO at Kymera Therapeutics. Learn More about Nello Mainolfi's net worth.

How old is Nello Mainolfi?

Dr. Mainolfi is currently 43 years old. There are 4 older executives and no younger executives at Kymera Therapeutics. Learn More on Nello Mainolfi's age.

What is Nello Mainolfi's salary?

As the CEO of Kymera Therapeutics, Inc., Dr. Mainolfi earned a total compensation package of $3,678,001.00 in 2020. Dr. Mainolfi earned a salary of $453,619.00, options awards of $2,845,382.00, non-equity compensation of $379,000.00, and no other miscellaneous compensation. Learn More on Nello Mainolfi's salary.

How do I contact Nello Mainolfi?

The corporate mailing address for Dr. Mainolfi and other Kymera Therapeutics executives is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. Kymera Therapeutics can also be reached via phone at 857-285-5300 and via email at [email protected] Learn More on Nello Mainolfi's contact information.

Has Nello Mainolfi been buying or selling shares of Kymera Therapeutics?

Nello Mainolfi has not been actively trading shares of Kymera Therapeutics within the last three months. Most recently, 0 shares of the company's stock in a transaction on Wednesday, May 18th. Learn More on Nello Mainolfi's trading history.

Who are Kymera Therapeutics' active insiders?

Kymera Therapeutics' insider roster includes Bruce Booth (Director), Richard Chesworth (Insider), Jared Gollob (Insider), Bruce Jacobs (CFO), and Nello Mainolfi (CEO). Learn More on Kymera Therapeutics' active insiders.

Are insiders buying or selling shares of Kymera Therapeutics?

In the last twelve months, Kymera Therapeutics insiders bought shares 5 times. They purchased a total of 1,097,242 shares worth more than $43,891,774.85. In the last twelve months, insiders at the sold shares 20 times. They sold a total of 579,112 shares worth more than $33,141,573.67. The most recent insider tranaction occured on May, 5th when Director Bvf Partners L P/Il bought 150,000 shares worth more than $2,940,000.00. Insiders at Kymera Therapeutics own 23.3 % of the company. Learn More about insider trades at Kymera Therapeutics.

Information on this page was last updated on 5/5/2022.

Nello Mainolfi Insider Trading History at Kymera Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/12/2022Sell8,612$52.08$448,512.96View SEC Filing Icon  
1/10/2022Sell22,465$53.26$1,196,485.90View SEC Filing Icon  
10/11/2021Sell6,456$53.68$346,558.08View SEC Filing Icon  
10/8/2021Sell41,544$56.76$2,358,037.44View SEC Filing Icon  
8/4/2021Sell1,037$60.03$62,251.11457,868View SEC Filing Icon  
8/2/2021Sell23,456$60.30$1,414,396.80452,879View SEC Filing Icon  
7/30/2021Sell6,279$60.07$377,179.53View SEC Filing Icon  
7/28/2021Sell3,864$60.15$232,419.60461,214View SEC Filing Icon  
7/26/2021Sell9,015$60.15$542,252.25461,214View SEC Filing Icon  
7/8/2021Sell48,000$49.70$2,385,600.00500,199View SEC Filing Icon  
6/9/2021Sell5,752$50.02$287,715.04424,923View SEC Filing Icon  
6/7/2021Sell12,724$50.14$637,981.36424,923View SEC Filing Icon  
5/12/2021Sell8,245$50.05$412,662.25405,444View SEC Filing Icon  
4/26/2021Sell2,768$40.18$111,218.24408,158View SEC Filing Icon  
4/23/2021Sell680$40.01$27,206.80408,158View SEC Filing Icon  
4/19/2021Sell653$40.00$26,120.00396,139View SEC Filing Icon  
4/15/2021Sell4,940$40.29$199,032.60396,139View SEC Filing Icon  
4/12/2021Sell15,267$32.62$498,009.54386,138View SEC Filing Icon  
4/9/2021Sell22,794$33.68$767,701.92386,138View SEC Filing Icon  
See Full Table

Nello Mainolfi Buying and Selling Activity at Kymera Therapeutics

This chart shows Nello Mainolfi's buying and selling at Kymera Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kymera Therapeutics Company Overview

Kymera Therapeutics logo
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $15.52
Low: $14.94
High: $17.11

50 Day Range

MA: $33.39
Low: $15.52
High: $43.31

2 Week Range

Now: $15.52
Low: $14.94
High: $69.12


842,320 shs

Average Volume

524,525 shs

Market Capitalization

$802.76 million

P/E Ratio


Dividend Yield



Copper More Critical than Lithium?
Lithium may have grabbed the headlines as a key material in building electric vehicles (EVs). But so is copper. And copper's importance in the new green economy goes far beyond EVs. Copper is critical in building wind turbines and solar panels. It's key to power lines and upgrading the national grid. Analysts say we're facing a 10-million-ton shortfall if new copper mines are not found.
See How To Can Benefit From New Copper Discoveries